1. Scrip
  2. >>Business
  3. >>Earnings

CEO Viehbacher Confident In Biogen’s Portfolio, But Open To Additions

Q4 Revenue In Line, Guidance Below Consensus

 
• By Mandy Jackson

As Biogen’s MS revenue continues its multi-year decline, the slow return to growth raises concerns about the company’s pipeline – but CEO Christopher Viehbacher said all is on track.

Biogen's Q4 sales were up 3% from Q4 2023, but full-year 2024 sales were down 2% (Shutterstock)

CEO Christopher Viehbacher has been straightforward about Biogen’s challenges since taking the helm in November 2022, and that did not change as the company reported its fourth-quarter and full-year 2024 earnings on 12 February. But he expressed confidence in the path forward based on Biogen’s new product launches and pared-down pipeline, while noting the company remains open to adding assets through deals.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

BMS Makes Dealmaking A Top Priority As Doubts About Growth Increase

 
• By Mandy Jackson

Bristol’s CEO Christopher Boerner says business development is the company’s biggest spending priority as analysts raise concerns about growth, citing a need for BMS to do more deals.

AbbVie Increases US Manufacturing, But Says It’s Not Because Of Tariffs

 
• By Joseph Haas

CEO Robert Michael said AbbVie is positioned strongly to handle current and potentially upcoming tariffs, while committing $10bn to increased US manufacturing sites.

Gilead Keeping Eye On Policy But Sees Little Impact From HHS Cuts, Tariffs

 
• By Alaric DeArment

The drugmaker said in its first quarter earnings that it did not foresee negative effects on potential approval and launch of lenacapavir for PrEP later this year.

Merck Forecast Incorporates $200m Tariff Hit

 
• By Joseph Haas

On a quarterly earnings call that touched on Trump administration policy impacts, Merck said it is well positioned for changes coming from the new administration.

More from Scrip

Merck KGaA Moves Closer To Sealing SpringWorks Buy

 
• By Kevin Grogan

The German group could pay $3.5bn to get hold of the US firm and its two approved products.

In Brief: Mosaic Gains Two Clinical-Stage Oncology Assets From Astex

 
• By Sushmita Panda

Mosaic Therapeutics has in-licensed two clinical-stage oncology assets from Astex Pharmaceuticals to develop proprietary combination therapies for hard-to-treat cancers. The deal includes up to a 22% equity stake for Astex, future revenue sharing, and a planned clinical study in 2026.

Executives On The Move: Ten CMOs And Three CEOs and CFOs Each Among This Week’s Changes

Recent moves in the industry include C-suite changes at Dyne Therapeutics, City Therapeutics and ProQR Therapeutics, plus Madrigal Pharmaceuticals acquires chief medical officer from Novartis.